332 related articles for article (PubMed ID: 21332734)
1. A review of the clinical implications of bisphosphonates in dentistry.
Borromeo GL; Tsao CE; Darby IB; Ebeling PR
Aust Dent J; 2011 Mar; 56(1):2-9. PubMed ID: 21332734
[TBL] [Abstract][Full Text] [Related]
2. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
3. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
Kunchur R; Need A; Hughes T; Goss A
J Oral Maxillofac Surg; 2009 Jun; 67(6):1167-73. PubMed ID: 19446200
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates and osteonecrosis of the jaws: science and rationale.
Gutta R; Louis PJ
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Aug; 104(2):186-93. PubMed ID: 17448709
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates and bisphosphonate induced osteonecrosis.
Sawatari Y; Marx RE
Oral Maxillofac Surg Clin North Am; 2007 Nov; 19(4):487-98, v-vi. PubMed ID: 18088900
[TBL] [Abstract][Full Text] [Related]
6. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
King AE; Umland EM
Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates and osteonecrosis of the jaws.
Mariotti A
J Dent Educ; 2008 Aug; 72(8):919-29. PubMed ID: 18676801
[TBL] [Abstract][Full Text] [Related]
8. Management of bisphosphonate-induced osteonecrosis of the jaw.
Schilling J
Northwest Dent; 2008; 87(3):34-5, 37-8, 40. PubMed ID: 18663869
[TBL] [Abstract][Full Text] [Related]
9. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study.
Lee CY; Suzuki JB
Implant Dent; 2010 Feb; 19(1):29-38. PubMed ID: 20147814
[TBL] [Abstract][Full Text] [Related]
10. CTX and its role in managing patients exposed to oral bisphosphonates.
Dodson TB
J Oral Maxillofac Surg; 2010 Feb; 68(2):487-8; author reply 488-9. PubMed ID: 20116729
[No Abstract] [Full Text] [Related]
11. Safety profile of intravenous bisphosphonates.
Mehrotra B
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S24-7. PubMed ID: 18068487
[TBL] [Abstract][Full Text] [Related]
12. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.
Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Al Mardini M; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; St-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
J Rheumatol; 2008 Jul; 35(7):1391-7. PubMed ID: 18528958
[TBL] [Abstract][Full Text] [Related]
13. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
; Khosla S; Burr D; Cauley J; Dempster DW; Ebeling PR; Felsenberg D; Gagel RF; Gilsanz V; Guise T; Koka S; McCauley LK; McGowan J; McKee MD; Mohla S; Pendrys DG; Raisz LG; Ruggiero SL; Shafer DM; Shum L; Silverman SL; Van Poznak CH; Watts N; Woo SB; Shane E
J Oral Maxillofac Surg; 2008 Jun; 66(6):1320-1; author reply 1321-2. PubMed ID: 18486811
[No Abstract] [Full Text] [Related]
14. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part I: biological concepts with a review of the literature.
Lee CY; Suzuki JB
Implant Dent; 2009 Dec; 18(6):492-500. PubMed ID: 20009603
[TBL] [Abstract][Full Text] [Related]
15. [Osteonecrosis of the jaw and bisphophonates in oncology].
Facon T; Bensadoun RJ; Blanc JL; Confavreux C; Gourmet R; Maes JM; Penel G; Vieillard MH; Woeller A
Bull Cancer; 2008 Apr; 95(4):413-8. PubMed ID: 18495570
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonate-related osteonecrosis of the jaw.
Feller L; Wood NH; Khammissa RA; Chikte UM; Bouckaert M; Lemmer J
SADJ; 2011 Feb; 66(1):30-2. PubMed ID: 21510174
[TBL] [Abstract][Full Text] [Related]
17. Osteonecrosis in the jaws of patients who are using oral biphosphonates to treat osteoporosis.
Dello Russo NM; Jeffcoat MK; Marx RE; Fugazzotto P
Int J Oral Maxillofac Implants; 2007; 22(1):146-53. PubMed ID: 17340909
[No Abstract] [Full Text] [Related]
18. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
Marx RE; Cillo JE; Ulloa JJ
J Oral Maxillofac Surg; 2007 Dec; 65(12):2397-410. PubMed ID: 18022461
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates and the dental patient: Part 2.
Zak M; Spina AM; Spinazze RP; Perkinson WL; Spinazze DJ
Compend Contin Educ Dent; 2007 Sep; 28(9):510-5; quiz 516, 528. PubMed ID: 17907374
[TBL] [Abstract][Full Text] [Related]
20. Osteonecrosis of the jaw and bisphosphonates--putting the risk in perspective.
Bolland M; Hay D; Grey A; Reid I; Cundy T
N Z Med J; 2006 Dec; 119(1246):U2339. PubMed ID: 17151713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
